Abstract
Immunotherapy has limited efficacy against locally advanced pancreatic cancer (LAPC) due to the presence of an immunosuppressive microenvironment (ISM). Irreversible electroporation (IRE) can not only induce immunogenic cell death, but also alleviate immunosuppression. This study aimed to investigate the antitumor efficacy of IRE plus allogeneic γδ T cells in LAPC patients. A total of 62 patients who met the eligibility criteria were enrolled in this trial, then randomized into two groups (A: n = 30 and B: n = 32). All patients received IRE therapy and after receiving IRE, the group A patients received at least two cycles of γδ T-cell infusion as one course continuously. Group A patients had better survival than group B patients (median OS: 14.5 months vs. 11 months; median PFS: 11 months vs. 8.5 months). Moreover, the group A patients treated with multiple courses of γδ T-cell infusion had longer OS (17 months) than those who received a single course (13.5 months). IRE combined with allogeneic γδ T-cell infusion is a promising strategy to enhance the antitumor efficacy in LAPC patients, yielding extended survival benefits.ClinicalTrials.gov ID: NCT03180437.
Highlights
Pancreatic adenocarcinoma (PDAC) is a disease associated with poor prognosis, which has an increasing impact on cancer-related mortality worldwide.[1]
Enrolled patients From June 2017 to June 2018, a total of 176 PDAC patients from 12 countries were enrolled after go through a screening process, 70 (39.8%) of them were confirmed for locally advanced pancreatic cancer (LAPC) (Supplementary Table 1)
The primary result of our study was the median overall survival (OS) in the participants with LAPC from diagnosis was 19 months, which was consistent with the previous result reported by Martin et al.[9]
Summary
Pancreatic adenocarcinoma (PDAC) is a disease associated with poor prognosis, which has an increasing impact on cancer-related mortality worldwide.[1]. The immunosuppressive microenvironment (ISM) can inhibit the activity of tumor infiltrating lymphocytes.[7,8] the novel and effective therapies for LAPC patients are needed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
